Acquisition of own shares by UCB SA/NV
BRUSSELS, Belgium, 19 May 2011 – 19:30 (CET) – regulated information - In application of art. 207 of the Royal Decree executing the Company Code, UCB publishes having acquired 25,900 UCB shares on the Brussels stock exchange on the dates and at the prices indicated hereunder:
Date | Amount | Price EUR |
12/05/2011 | 2,500 | 32.530 |
12/05/2011 | 2,500 | 32.110 |
12/05/2011 | 7,400 | 32.150 |
13/05/2011 | 4,700 | 33.300 |
13/05/2011 | 1,300 | 32.405 |
13/05/2011 | 1,900 | 32.500 |
16/05/2011 | 2,500 | 32.480 |
16/05/2011 | 1,000 | 32.805 |
17/05/2011 | 100 | 32.270 |
18/05/2011 | 2,000 | 32.310 |
These shares were immediately distributed to the employees who have exercised share options that had been granted to them in the framework of existing Company’s share option plans of which the detail is given in UCB annual report.
UCB has also acquired 1,114,259 shares on 13 May 2011 over the counter at a price of €33.0033 (which was the volume weighted average price at that day). The highest Brussels stock exchange price on 13 May 2011 was €33.45.
As a consequence, the new weighted average number of ordinary shares1 (used to calculate the earnings per share of the company) as of today is 179 million after 180 million on 31 December 2010.
UCB S.A. - Allée de la Recherche, 60 - 1070 Bruxelles - RPM 0403.053.608
[1] Weighted average number of ordinary shares: The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of shares bought back or issued during the period, multiplied by a time-weighting factor.
For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, antje.witte@ucb.com
Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, Michael.tuck-sherman@ucb.com
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).
Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.
Asset Download
Stay up-to-date on the latest news and information from UCB